5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole | 618910-05-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
• 英文别名: 5-benzyl-1,2,3,4-tetrahydropyrido[4,3-b]indole
• CAS: 618910-05-7
• 化学式: C₁₈H₁₈N₂
• mdl: MFCD13252134
• 分子量: 262.354
• InChiKey: MLJFUGARSRPYSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole 在 盐酸羟胺 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 24.0h， 生成 4-(5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole-2-carbonyl)-N-hydroxybenzamide
  参考文献：
  名称：

  靶向相关 HDAC 以支持遗传性视网膜疾病中视锥光感受器的存活：鉴定具有体外和体内功效的有效药理学工具

  摘要：

  遗传性视网膜疾病，包括色素性视网膜炎，是一类遗传性疾病，其特征是逐渐的视锥细胞变性和视力丧失，且没有有效的药物治疗。实验方法旨在延缓疾病进展，支持视锥细胞的生存，这对人类视觉至关重要。组蛋白脱乙酰酶 (HDAC) 介导表观遗传和非表观遗传途径的激活，从而调节 RP 小鼠模型中的视锥细胞变性。我们开发了新的 HDAC 抑制剂 ( 5a – p )，以四氢-γ-咔啉支架为代表，其特点是具有高 HDAC6 抑制效力和平衡的理化特性，适合体内研究。与 ARPE-19 和 661W 细胞中的组蛋白 H3 相比，化合物5d （ repistat ，IC 50 HDAC6 = 6.32 nM）增加了乙酰化 α-微管蛋白的水平。 5d促进了atp6v0e1 –/–光感受器功能障碍斑马鱼模型的视力挽救。在 RP rd10小鼠模型中单次玻璃体内注射5d支持视锥细胞的形态和功能保存以及视网膜色素上皮阵列的维持。

  DOI：

  10.1021/acs.jmedchem.4c00477
• 作为产物：
  描述：

  1,3,4,5-四氢-2H-吡啶并[4,3-b]吲哚-2-甲酸乙酯 在 氢氧化钾 、 sodium hydride 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.25h， 生成 5-benzyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole
  参考文献：
  名称：

  γ-Carbolines: binding at 5-HT5A serotonin receptors

  摘要：

  Screening of various agents resulted in the identification of 5-methyl-1,2,3,4-tetrahydro-gamma-carboline (1; K-i = 5,300 nM) as a compound with modest affinity for mouse 5-HT5A receptors. Structure-affinity studies were conducted resulting in 5-methyl-2-[3-(4-fluorophenoxy)propyl]- 1,2,3,4-tetrahydro-gamma-carboline (17; K-i = 13 nM). Although 17 also binds at 5-HT2 receptors, it serves as a novel lead for the further development of 5-HT5A ligands. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00527-8

文献信息

• LIGANDS OF ALPHA-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF
  申请人：Alla Chem, LLC.

  公开号：EP2236511A2

  公开（公告）日：2010-10-06

  The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C1-C4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C1-C4 alkyl, CF3, CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH2)m group, optionally substituted CH=CH group, optionally substituted CH2-CH=CH group, C≡C group, SO2 group; n = 1, 2; m = 1, 2, 3; solid line accompanied by dotted line, i.e. (---) may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.

  本发明涉及新型配体，其广泛的生物活性同时包括α-肾上腺素受体、多巴胺受体、组胺受体、咪唑啉受体和血清素受体，其中包括血清素5-HT7受体，这些配体是通式1化合物，其形式为游离碱、几何异构体、外消旋混合物或单个光学异构体、药学上可接受的盐和/或水合物、 其中R1 是氨基的取代基，选自氢、任选取代的 C1-C4 烷基、酰基、杂环基、烷氧羰基、取代的磺酰基； R2 是环状体系的取代基，选自氢、卤素、任选取代的 C1-C4 烷基、CF3、CN、烷氧基、烷氧羰基、羧基、杂环基或取代的磺酰基；Ar 是任选取代的芳基，不一定是环状杂环基，或任选取代的芳香族杂环基； W 是任选取代的 (CH2)m 基团、任选取代的 CH=CH 基团、任选取代的 CH2-CH=CH 基团、C≡C 基团、SO2 基团；n = 1、2；m = 1、2、3；实线伴有虚线，即.即（---）可代表单键或双键。 本发明还涉及活性成分、包含上述配体作为活性成分的药物组合物；涉及用于治疗人类和温血动物中枢神经系统（CNS）疾病和病症的新型药物。
• LIGANDS OF ALPHA-ADRENOCEPTORS, DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THEIR USE
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20110039825A1

  公开（公告）日：2011-02-17

  The invention relates to novel ligands the broad spectrum of biological activity of which includes simultaneously α-adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, among them serotonin 5-HT 7 receptors, which are compounds of general formula 1 in the form of free bases, geometrical isomers, racemic mixtures or individual optical isomers, pharmaceutically acceptable salts and/or hydrates, wherein: R1 is a substituent of amino group, selected from hydrogen, optionally substituted C 1 -C 4 alkyl, acyl, heterocyclyl, alkoxycarbonyl, substituted sulfonyl; R2 is a substituent of cyclic system, selected from hydrogen, halogen, optionally substituted C 1 -C 4 alkyl, CF 3 , CN, alkoxy, alkoxycarbonyl, carboxyl, heterocyclyl or substituted sulfonyl; Ar is optionally substituted aryl not necessarily annalated with heterocyclyl, or optionally substituted aromatic heterocyclyl; W is optionally substituted (CH 2 ) m group, optionally substituted CH═CH group, optionally substituted CH 2 —CH═CH group, C≡C group, SO 2 group; n=1, 2; m=1, 2, 3; solid line accompanied by dotted line, i.e. may represent single or double bond. The invention also relates to active ingredients, pharmaceutical compositions comprising the said ligands as active ingredients; to novel medicaments useful for treatment of diseases and conditions of central nervous system (CNS) of humans and warm-blooded animals.
• [EN] LIGANDS OF a-ADRENOCEPTORS AND OF DOPAMINE, HISTAMINE, IMIDAZOLINE AND SEROTONIN RECEPTORS AND THE USE THEREOF<br/>[FR] LIGANDS DALPHA-ADRÉNORÉCEPTEURS, DE RÉCEPTEURS DE DOPAMINE, DE L'HISTAMINE, D'IMIDAZOLINE ET DE SÉROTONINE AINSI QUE LEURS PROCÉDÉS D'UTILISATION
  申请人：ALLA CHEM LLC

  公开号：WO2009082268A2

  公开（公告）日：2009-07-02

  Данное изобретение относится к новым лигандам, широкий спектр биологической активности которых включает одновременно альфа-адреноцепторы, допаминовые рецепторы, гистаминовые рецепторы, имидазолиновые рецепторы и серотониновые рецепторы, в том числе и серотониновые 5-HT7 рецепторы, представляющим собой соединения общей формулы 1 в виде свободных оснований, геометрических изомеров, рацемических смесей или индивидуальных оптических изомеров, а также в виде фармацевтически приемлемых солей и/или гидратов, где: Rl представляет собой заместитель аминогруппы, в том числе атом водорода, необязательно замещенный C1-C4 алкил, ацил, гетероциклил, алкоксикарбонил, замещенный сульфонил; R2 представляет собой заместитель циклической системы, в том числе атом водорода, атом галогена, необязательно замещенный C1-C4 алкил, CF3, CN, алкокси, алкоксикарбонил, карбоксил, гетероциклил или замещенный сульфонил; Ar - представляет собой необязательно замещенный арил, возможно аннелированный с гетероциклилом, или необязательно замещенный гетероциклил; W представляет собой необязательно замещенную (CH2)m группу, необязательно замещенную CH=CH группу, необязательно замещенную CH2-CH=CH группу, необязательно замещенную G≡С группу, группу SO2; n = 1 или 2; m = 1, 2 или 3; сплошная линия с сопровождающей ее пунктирной линией (---) представляет одинарную или двойную связь. Изобретение также относится к лекарственным субстанциям, фармацевтическим композициям, содержащим в качестве лекарственных субстанций новые лиганды, к новым лекарственным средствам, применяемым для лечения болезней и состояний центральной нервной системы людей и теплокровных животных.
• γ-Carbolines: binding at 5-HT5A serotonin receptors
  作者：Nantaka Khorana、Anil Purohit、Katherine Herrick-Davis、Milt Teitler、Richard A. Glennon

  DOI：10.1016/s0968-0896(02)00527-8

  日期：2003.3

  Screening of various agents resulted in the identification of 5-methyl-1,2,3,4-tetrahydro-gamma-carboline (1; K-i = 5,300 nM) as a compound with modest affinity for mouse 5-HT5A receptors. Structure-affinity studies were conducted resulting in 5-methyl-2-[3-(4-fluorophenoxy)propyl]- 1,2,3,4-tetrahydro-gamma-carboline (17; K-i = 13 nM). Although 17 also binds at 5-HT2 receptors, it serves as a novel lead for the further development of 5-HT5A ligands. (C) 2002 Elsevier Science Ltd. All rights reserved.
• 10.1021/acs.jmedchem.4c00477
  作者：Carullo, Gabriele、Orsini, Noemi、Piano, Ilaria、Pozzetti, Luca、Papa, Alessandro、Fontana, Anna、Napoli, Debora、Corsi, Francesca、Marco, Beatrice Di、Galante, Alessia、Marotta, Ludovica、Panzeca, Giovanna、O’Brien, Justine、Sanchez, Alicia Gomez、Doherty, Harry、Mahon, Niamh、Clarke, Leni、Contri, Chiara、Pasquini, Silvia、Gorelli, Beatrice、Saponara, Simona、Valoti, Massimo、Vincenzi, Fabrizio、Varani, Katia、Ramunno, Anna、Brogi, Simone、Butini, Stefania、Gemma, Sandra、Kennedy, Breandán N.、Gargini, Claudia、Strettoi, Enrica、Campiani, Giuseppe

  DOI：10.1021/acs.jmedchem.4c00477

  日期：——

  Inherited retinal diseases, which include retinitis pigmentosa, are a family of genetic disorders characterized by gradual rod-cone degeneration and vision loss, without effective pharmacological treatments. Experimental approaches aim to delay disease progression, supporting cones’ survival, crucial for human vision. Histone deacetylases (HDACs) mediate the activation of epigenetic and nonepigenetic

  遗传性视网膜疾病，包括色素性视网膜炎，是一类遗传性疾病，其特征是逐渐的视锥细胞变性和视力丧失，且没有有效的药物治疗。实验方法旨在延缓疾病进展，支持视锥细胞的生存，这对人类视觉至关重要。组蛋白脱乙酰酶 (HDAC) 介导表观遗传和非表观遗传途径的激活，从而调节 RP 小鼠模型中的视锥细胞变性。我们开发了新的 HDAC 抑制剂 ( 5a – p )，以四氢-γ-咔啉支架为代表，其特点是具有高 HDAC6 抑制效力和平衡的理化特性，适合体内研究。与 ARPE-19 和 661W 细胞中的组蛋白 H3 相比，化合物5d （ repistat ，IC 50 HDAC6 = 6.32 nM）增加了乙酰化 α-微管蛋白的水平。 5d促进了atp6v0e1 –/–光感受器功能障碍斑马鱼模型的视力挽救。在 RP rd10小鼠模型中单次玻璃体内注射5d支持视锥细胞的形态和功能保存以及视网膜色素上皮阵列的维持。